ArticlePLoS neglected tropical diseases2026
Performance of fecal inflammatory biomarkers to identify watery shigellosis: Findings from the Enterics for Global Health (EFGH) Shigella surveillance study.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent syndromic guidelines for diarrhea treatment miss watery Shigella cases, leading to undertreatment of children who may benefit. Incorporating fecal inflammatory biomarkers into diagnosis may improve case identification.
methodsWe conducted an ancillary analysis using samples from six sites (The Gambia, Kenya, Malawi, Bangladesh, Pakistan, and Peru) from the Enterics for Global Health (EFGH)-Shigella surveillance study, a facility-based hybrid study of children aged 6-35 months with diarrhea. Four fecal biomarkers were quantified by enzyme-linked immunosorbent assays at enrollment: myeloperoxidase, calprotectin, neutrophil gelatinase-associated lipocalin (lipocalin-2), and hemoglobin. An ensemble model with leave-one-site-out cross-validation was used to predict watery shigellosis, incorporating biomarkers and nine clinical and socio-economic predictors. We compared the predictive performance of the algorithm using: a) all predictors (including biomarkers); b) all non-biomarker predictors; c) all predictors (with selected biomarkers).
resultsBetween June 2022 and August 2024, a total of 4,191/9,476 (44.2%) children presented with watery diarrhea (non-bloody) and had their whole stool tested for the biomarkers and 4,083 stool samples or rectal swabs were tested by qPCR; 735 (18.0%) had Shigella-attributable diarrhea by qPCR. The full model incorporating all 13 predictors achieved an area under the curve (AUC) of 0.75 [95% CI: 0.67-0.78], with a sensitivity of 0.67 and specificity of 0.75. Excluding biomarkers reduced model performance by 8% (AUC 0.67, 95% CI: 0.61-0.70). Adding hemoglobin alone improved the model's discriminatory ability by 7%, while further adding myeloperoxidase had marginal contribution (1%), and lipocalin-2 (0%) and calprotectin none (0%).
conclusionFecal hemoglobin substantially improved prediction scores for watery shigellosis. Consequently, implementation of point-of-care assays for hemoglobin could improve clinical diagnosis in these settings and inform appropriate antibiotic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.